Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has reported its financial results for the first half of 2026, highlighting a significant increase in revenue and the progression of an expanded clinical manufacturing program in the United States. The company, which combines therapeutic development with a revenue-generating contract development and manufacturing organization (CDMO), saw revenue climb to $949,000, up from $773,000 in the same period last year. Committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, with about $2.1 million already invoiced.
The company is advancing an expanded clinical manufacturing and chemistry, manufacturing, and controls (CMC) program for a U.S.-based biopharmaceutical company. This initiative has already generated approximately $650,000 in cash payments and advances, with substantive activities underway while a definitive agreement remains under negotiation. The program is designed to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. Scinai continues to target approximately $5 million in CDMO revenue for 2026.
Financially, Scinai reported an operating loss of approximately $4.6 million for the first half, compared with $3.8 million a year earlier. However, net income swung to a positive $1.6 million, versus a net loss of approximately $4.1 million in the prior-year period. This improvement was primarily driven by a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. Cash, cash equivalents, and restricted cash totaled approximately $2.9 million as of June 30, 2026.
In addition to its CDMO activities, Scinai continues to advance its PC111 and NanoAbs therapeutic programs. The company will host an investor webinar on Aug. 26, 2026, to discuss recent developments, financial performance, and upcoming milestones. For more details, the full press release is available at https://nnw.fm/Be7Ky.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. Its pipeline includes therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. The company also owns Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel. The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI.
